STOCK TITAN

Metagenomi trial cleared; start planned for H2 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Metagenomi Therapeutics, Inc. (MGX) said its lead candidate MGX-001 has an IND cleared to begin the INTEGR8 Phase 1/2 trial in adults with moderately severe to severe hemophilia A. The company plans to start with adults and expand to adolescents and children. Its timeline lists clinical trial application submissions outside the U.S. in the first half of 2027 and trial initiation in the second half of 2027.

Metagenomi reported $101.7 million in cash at the end of Q3 2026, including cash equivalents and available-for-sale marketable securities, and said its anticipated runway supports operations into 2028. The presentation describes MGX-001 as using CRISPR-mediated integration of a Factor VIII gene at the albumin locus. In preclinical work, the company reported stable FVIII expression over approximately 19 months in nonhuman primates and no off-target edits at 623 candidate sites tested in primary human hepatocytes. Its Ionis partnership lists four cardiometabolic targets and two co-development and co-commercialization options.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointMGX-001’s IND is cleared for the planned Phase 1/2 hemophilia A trial.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents and available-for-sale marketable securities $101.7 million At the end of Q3 2026; the presentation defines this as cash.
Anticipated cash runway Into 2028 Expected period of operations support stated by the company.
IND clearance Phase 1/2 trial MGX-001’s INTEGR8 study in hemophilia A.
Preclinical FVIII expression Approximately 19 months Stable expression reported in a nonhuman-primate study.
Potential off-target editing sites tested 623 sites No off-target edits identified in primary human hepatocytes at the tested doses.
Hemophilia A patients in the U.S. Approximately 25,000 patients Patient estimate cited in the presentation.
Hemophilia A patients worldwide Approximately 500,000 patients Patient estimate cited in the presentation.
ATXN2 protein knockdown 64% Reported for compact nuclease MG119-28 in mouse brain.
IND regulatory
"IND cleared to initiate INTEGR8 Phase 1/2 trial"
site-specific large gene integration technical
"Leverage site-specific large gene integration across additional indications"
albumin locus technical
"Cut at albumin locus and FVIII gene integrates"
The albumin locus is the specific place on a genome that contains the albumin gene and the nearby DNA elements that control its activity; it includes the gene’s coding sequence, promoters, enhancers and often adjacent related genes from the same gene family. In practical use this term identifies the genomic region targeted in laboratory assays, genetic studies or therapeutic approaches, and its exact DNA sequence and regulatory structure can differ between species and individuals.
FVIII medical
"MGX-001: leveraging natural promoter to drive durable Factor VIII (FVIII) production"
Factor VIII (often written FVIII) is a protein in the blood that helps form clots and stop bleeding; people with low or absent FVIII have a bleeding disorder called hemophilia A. It matters to investors because therapies, drugs, or diagnostics that replace, mimic, or modify FVIII are central to large clinical programs and markets; success or failure in developing FVIII-related treatments can affect regulatory outcomes, revenue forecasts, and a company’s valuation, much like a key ingredient determines a recipe’s outcome.
AAV technical
"AAV delivers FVIII gene"
AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.
off-target edits technical
"No off-target edits identified in PHH at any dose"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does MGX-001’s INTEGR8 trial plan to begin?

Metagenomi’s timeline lists initiation in the second half of 2027, following planned clinical trial application submissions outside the U.S. in the first half of 2027.

How did Metagenomi assess potential off-target editing by MGX-001?

The company tested 623 potential off-target sites in primary human hepatocytes from three human donors at 1x, 8x and 32x the dose that produces 90% of maximal on-target editing; it reported no off-target edits at any dose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000178527900017852792026-11-162026-11-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

Metagenomi Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41949

81-3909017

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

5959 Horton Street

7th Floor

 

Emeryville, California

 

94608

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (510) 871-4880

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

MGX

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 


Item 7.01 Regulation FD Disclosure.

A copy of the Metagenomi Therapeutics, Inc. November 2026 corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

 

Description

99.1

 

Corporate Presentation of Metagenomi Therapeutics, Inc. dated November 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Metagenomi Therapeutics, Inc.

 

 

 

 

Date:

November 16, 2026

By:

/s/ Jian Irish

 

 

 

Jian Irish, Ph.D., M.B.A.
President and Chief Executive Officer

 


Slide 1

Precision gene editing designed to deliver durable, curative medicines Corporate Presentation November 2026


Slide 2

This presentation includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward looking statements, including the timing of and our ability to make regulatory filings such as INDs, the design and timing of the INTEGR8 trial and initial clinical data, expectations regarding MGX-001 including the preclinical profile with best-in-class treatment potential, statements regarding the Company’s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones, statements concerning the potential of therapies and product candidates, statements concerning the impact of organizational restructuring, statements concerning our anticipated cash runway, and any other statements that are not historical facts. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including but not limited to risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; the risk that the FDA or other regulatory authorities may place a clinical hold on our clinical trials or that initiation of our clinical trials may be delayed; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; and other risks, uncertainties and assumptions identified in our filings with the Securities and Exchange Commission (the “SEC”), including our most recent Form 10-K and Form 10-Q filed with the SEC, and any subsequent filings with the SEC.  Moreover, we operate in a very competitive and rapidly changing environment, and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking statements and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, unless required by law. This presentation contains estimates and other information concerning our industry, our business and the markets for our products. Information that is based on estimates, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. These sources include government and industry sources. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the industry and market data to be reliable as of the date of this presentation, this information could prove to be inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. While we believe our internal company estimates and research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source, and no reliance should be placed on or should be made on any information or statements made in this presentation relating to or based on such internal estimates and research. Forward-looking statements


Slide 3

A differentiated in vivo gene editing company advancing potentially curative genetic medicines 1 Cash includes cash, cash equivalents and available-for-sale marketable securities 2 As filed in the Company’s Form 10-Q for Q3 2026 earnings on November 10, 2026 An in vivo CRISPR gene editing company capitalizing on proprietary technologies to create potentially curative genetic medicines Focusing on lead program MGX-001 in hemophilia A advancing to the clinic with clear development path and well-defined clinical endpoints Expanding indications by leveraging differentiated site-specific large gene integration systems and partnered assets targeting cardiometabolic indications $101.7 million in cash1 at end of Q3 2026; Runway anticipated to support operations into 20282


Slide 4

20,000 + Differentiated and proprietary gene editing technologies Suite of novel editing tools from Metagenomi’s unique database High specificity Precise editing Multiplexed editing Multi-target capability Durability Long term effectiveness Broad targeting Expanded genome access We improve editing precision and expand genome targeting and editing functionality beyond CRISPR/Cas9 to effectively address diseases with an underlying genetic cause.


Slide 5

A versatile platform designed to address a wide range of genetic diseases Potentially capable of correcting any type of genetic mutation found anywhere in the human genome Metagenomi
Technology Large Gene Integration Protein replacement Gene editing in the presence of DNA templates to allow for site-specific gene integration Protein Knockdown Cardiometabolic pathways Programmable nucleases or base editors make deletions or change a single base to cause protein knockdown Precision Corrections Genetic disorders Gene correction by single nucleotide changes delivered as RNA Multiplex Editing Cell therapy Simultaneous multiplexed base editing for protein knockdown and site-specific transgene insertion Knockdown & Correction CNS & muscle Compact nucleases and base editors delivered by AAV to extrahepatic tissues


Slide 6

Protein replacement via gene insertion Protein reduction via gene knockout ALB MGX-001 Hemophilia A Undisclosed Undisclosed TTR AGT APOC3 Undisclosed Cardiometabolic Diseases Editing platform: Editing target: Discovery Lead optimization IND-enabling Clinical Indication: Focused pipeline anchored by differentiated gene editing technologies Metagenomi is exploring opportunities to pursue neuromuscular disease targets & liver disease targets such as A1AT and Wilson Disease, as well as business development to expand therapeutic applications including cell therapy.


Slide 7

MGX-001 - designed to deliver a durable, one-time treatment for hemophilia A


Slide 8

AAV delivers FVIII gene LNP delivers CRISPR cargo CRISPR cargo forms complex Cut at albumin locus and FVIII gene integrates Albumin promoter drives sustained FVIII production MGX-001: leveraging natural promoter to drive durable Factor VIII (FVIII) production AAV delivers donor DNA: Promoterless FVIII gene MGX-001 components: Guide RNA (gRNA) Nuclease mRNA (MG29-1) LNP delivers CRISPR nuclease mRNA & gRNA targeting albumin AAV cell nucleus DNA LNP gRNA MG29-1 FVIII protein albumin promoter RNP complex FVIII gene 1 2 3 4 5


Slide 9

~25,000 patients in the U.S.2 Hemophilia A: potentially life-threatening, blood-clotting disease with high treatment burden - Stonebraker, J. S., et al, 2010. Haemophilia. Vol. 16, pp. 20–32 - CDC Surveillance 2024 - World Federation of Hemophilia Bleeding Disorders Registry, 2023 Hemophilia A is caused by variety of mutations in the Factor VIII (FVIII) gene all leading to loss of functional FVIII protein. Lack of FVIII protein disrupts normal clotting cascade and increases bleeding. Repeated bleeding episodes in joints or soft tissues lead to progressive joint damage, inflammation and pain. 1 IND cleared to initiate INTEGR8 phase 1/2 trial in adult patients with moderately severe to severe hemophilia A Plan to initiate with adult patients and expand to adolescent and pediatric patients ~500,000 patients worldwide1 Hemophilia A is the most common X-linked inherited and de novo bleeding disorder, largely affecting males (~50% of patients severe; ~30% of patients moderate3 )


Slide 10

Hemophilia A unmet needs: high treatment burden and lack of durable cure - ICER. Gene Therapy for Hemophilia B and A: Final Evidence Report. Dec 22, 2022. - Curtis R., et al. Poster presented at: 65th ASH Annual Meeting & Exposition; December 11, 2023; San Diego, CA. Current Standard of Care: Factor VIII replacement therapy IV typically dosed 1 - 3 times/week, significant adherence challenges Frequent infusions and short half-life lead to FVIII peaks and troughs Ongoing risks of breakthrough and micro bleeds resulting in cumulative joint damage Non-factor bispecific "mimetic" SQ dosed 1, 2 or 4 weeks post loading, challenging FVIII monitoring Only ~10-15% FVIII-equivalent protection; require FVIII supplementation for serious injury or surgery Ongoing risks of breakthrough bleeds Risks of microbleeds and late-onset arthropathy unclear Unpredictable efficacy Lack of durability with declining FVIII Prolonged corticosteroid use Not suitable for pediatric patients Annual treatment cost1: ~$565K - $750K Lifetime treatment cost2: ~$18M - $24M FVIII Recently Withdrawn Gene Therapy:


Slide 11

Strong advocacy and infrastructure Robust preclinical models and regulatory familiarity Clearly defined target threshold for functionally curative FVIII level & wide safety range Monogenic and well-characterized biology with clear biomarker Genome editing offers a potentially durable, one-time treatment for hemophilia A Site-specific large gene integration IND cleared to initiate INTEGR8 study Technology: Durability: Regulatory status: Pediatric potential: Hemophilia A represents clear opportunity for a curative treatment: MGX-001 seeks to provide precise gene editing and direct integration into chromosome: MGX-001 is a potentially durable, one-time treatment for patients – the pediatric population has the most to gain


Slide 12

Normal physiological FVIII range achieved in preclinical model FVIII activity for each animals is the mean of values on d5, d8, d11 post LNP dosing measured with a capture-chromogenic assay. hFVIII activity was stable from d5 to d11 post LNP. Xyntha was used for the standard curve. Normal FVIII range Development candidate 25 15 0 50 75 100 125 150 hFVIII Activity (IU/dL) Group 6 Group 5 Group 2 Group 4 AAV dose (vg/kg): 5x1011 1.6x1012 5x1012 4x1013 LNP dose (mg/kg): 0.6 hFVIII Activity (IU/dL) 25 15 0 50 75 100 125 150 Group 2 Group 3 5x1012 0.6 2.0 Group 1 0.2 AAV dose (vg/kg): LNP dose (mg/kg): Dose range finding study in NHP: Confirmed clear dose-response relationship Identified minimal / optimal doses Achieved FVIII activity in normal range


Slide 13

Durable FVIII expression demonstrated ~19 months cFVIII NHP durability study: Stable expression over ~19 months Plasma cFVIII activity levels unchanged between 3-6 months and 12-19 months and correlate to integration Cynomolgus FVIII (cFVIII) activity values are the mean and standard deviation of at least three independent assay runs with each sample run in at least duplicate in each assay. Animal 1003 died on day 540 (17.8 mo) post LNP, assessed as unrelated to the treatment. 1 - Integration in forward orientation (copies per 100 haploid genomes, average of 5 liver lobes). Pre-development candidate 0 20 40 60 80 100 cFVIII Activity (IU/dL) 1001 3-6 12-19 1002 3-6 12-19 1003 3-6 12-18 Animal ID: Ratio cFVIII activity/integration1 0 5 10 15 1001 1002 1003 0 50 100 150 200 250 300 350 400 450 500 550 600 100 75 50 25 0 125 1001 1003 40% 15% 1002 cFVIII Activity (IU/dL) Days post LNP dosing 100% Animal ID: Month:


Slide 14

Off-target evaluation confirmed gene editing safety profile Discovery of potential off-target sites Identified 623 potential off-target editing sites using industry standard orthogonal methods Development candidate On-target site Evaluation of potential off-target sites In silico prediction In cell detection In vitro biochemical cleavage of human genomic DNA Abbreviations: PHH = Primary Human Hepatocytes 1 x dose = dose that results in 90% of maximal on-target editing (EC90) 32 x dose = 32 x EC90 Tested 623 potential sites in PHH from 3 human donors edited with 3 doses (1x, 8x, 32x) of MGX-001 No off-target edits identified in PHH at any dose, including super-saturating doses far exceeding the therapeutic dose


Slide 15

Novel mechanism of action integrates gene directly into chromosome FVIII integration leveraging albumin promoter to achieve rapid onset of normal FVIII activity level Lower dose of promoterless AAV designed to deliver safety advantage over traditional gene therapy Precise FVIII integration facilitated by proprietary CRISPR gene edit Extensive and supportive preclinical data set in NHPs FVIII activity achieved in normal physiologic range with clear dose response Durable FVIII activity over approximately 19-month study Encouraging safety profile with minimal corticosteroids and no genotoxicity observed Compelling potential clinical profile Enables endogenous production of FVIII supporting hemostatic regulation Potential to normalize FVIII levels and deliver meaningful clinical benefit for both adults and pediatric patients IND cleared for initiation of INTEGR8 trial Compelling preclinical profile achieved across efficacy, durability, and safety


Slide 16

Pre-IND Meeting Dec 2025 FDA meeting — collaborative, favorable outcome IND Cleared IND clearance for INTEGR8, first-in-human Phase 1/2 trial Initiation of CTA submissions ex-US 1H 2027 Initiate Clinical Trial Initiate INTEGR8 global multi-center, single-arm, open label Phase 1/2 trial CTAs approval ex-US 2028 and beyond Dose Expansion Cohort expansion at dose achieving target FVIII activity level in normal physiologic range Expansion to adolescent and pediatric patients MGX-001: INTEGR8 Phase 1/2 study timeline Goal: To develop a one-time durable therapy for adults and children with hemophilia A 2H 2027 Dose Escalation Initial clinical data including safety, tolerability and FVIII functional activity Q4 2025 Q4 2026


Slide 17

Broadening therapeutic potential with transformative gene editing  


Slide 18

Leverage site-specific large gene integration across additional indications Potential to substitute therapeutic transgene delivered by site-specific large gene integration to address additional diseases Achieved normal circulating levels of target protein in an additional disease Minimal target level Increase in Target Protein over baseline (ug/mL)* LNP delivers nuclease mRNA and guide targeting albumin site AAV delivers transgene (promoterless donor DNA) gRNA MG-Cas-RNA


Slide 19

Multiplex editing and compact editors enable next-generation therapies Combined protein knockdown and CAR knock-in in a single-step for cell therapy applications Compact nucleases and base editors demonstrated high editing efficiency and compatibility with AAV for extrahepatic delivery2,3  Four-plex knockdown and dual CAR knock-in in T cells with MGABE100 + 5 gRNA + DNA CAR template1    Multiple compact base editors2 demonstrated effective neuromuscular targeting Compact nuclease MG119-28 achieved 64% knockdown of ATXN2 protein in mouse brain4 Multiplex editing in T-cells achieved across seven unique gene targets with high efficiency comparable to single plex editing 1. van Overbeek, M., et al, Presentation at 10th Annual CAR TCR Summit, 2025 2. Rallapalli, R., et al, Submitted, 2026 3. Guan, K., et al, Nature Structural and Molecular Biology, 2026 4. Senger, K., et al, Poster presented at ASGCT Annual Meeting, 2025


Slide 20

All four targets in Wave 1 are in the lead optimization phase of development and are designed to achieve protein reduction via gene knockout. Strategic partnership for protein knockdown programs expands reach into large cardiometabolic markets TTR AGT APOC3 Undisclosed Current indications: MGX's in vivo genome editing complements Ionis leadership in cardiometabolic space 4 targets: two co-development and co-commercialization options Multibillion dollar TAM1  1. TAM = Total Addressable Marked


Slide 21

Metagenomi pipeline and expected updates Protein replacement via gene insertion Protein reduction via gene knockout ALB MGX-001 Hemophilia A Undisclosed Undisclosed TTR AGT APOC3 Undisclosed Cardiometabolic Diseases Editing platform: Editing target: Discovery Lead optimization IND-enabling Clinical Indication: Metagenomi is exploring opportunities to pursue neuromuscular disease targets & liver disease targets such as A1AT and Wilson Disease, as well as business development to expand therapeutic applications including cell therapy. INTEGR8 trial in 2027


Slide 22

Thank you

Filing Exhibits & Attachments

2 documents

Keep reading